Google
×
AllImagesBooksNews Maps Videos Shopping
Search tools

Multiple myeloma current treatment algorithms - Blood Cancer Journal

Nature
In this paper, we provide algorithms for the treatment of newly diagnosed and relapsed MM based on the best available evidence.
48 months ago

Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

The New England Journal of Medicine
High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide,...
82 months ago

Treatment Considerations for Transplant-Ineligible Multiple Myeloma

Cancer Network
In this review, we discuss assessment of frailty and focus on treatment options in both the newly diagnosed and relapsed/refractory settings for TI patients.
41 months ago

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis

Nature
Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). Unlike lenalidomide, the role of bortezomib in...
55 months ago

Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City

Cureus
Patients with “penta-refractory” multiple myeloma (MM) are challenging to treat given the limited treatment options available to them.
13 months ago

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

The New England Journal of Medicine
Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous...
92 months ago

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Nature
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma...
45 months ago

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Nature
Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems an effective treatment...
130 months ago

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

Nature
We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by...
71 months ago

Management of cardiovascular risk in patients with multiple myeloma | Blood Cancer Journal

Nature
MM can cause cardiac comorbidities such as cardiomyopathy and heart failure caused by cardiac amyloidosis and/or anemia.
67 months ago